A client’s BLA was exposed by a complex glycan profile and unresolved CMC gaps that risked delaying submission. We developed and validated a scale-down model to characterize the product and close those gaps before filing.
Impact for the client:
- Scale-down model validated for a complex glycan profile
- Critical CMC gaps closed ahead of submission
- BLA submitted on schedule
- FDA approval achieved
